Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13055402 | 0.86 | CYP17A1 (0.59) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL418939 | 0.85 | CYP17A1 (0.54) | CYP17A1PSMB8NAMPTHDAC3HDAC1 | |
| SCHEMBL7139404 | 0.83 | TGM2 (0.59) | CYP17A1PSMB8NAMPT | |
| SCHEMBL596259 | 0.82 | HDAC3 (0.50) | CYP17A1PSMB8NAMPTHDAC3HDAC1 | |
| SCHEMBL27794510 | 0.82 | CYP17A1 (0.51) | CYP17A1PSMB8NAMPTHDAC3HDAC1 | |
| SCHEMBL596258 | 0.82 | HDAC3 (0.50) | CYP17A1PSMB8NAMPTHDAC3HDAC1 | |
| SCHEMBL10045883 | 0.82 | HDAC3 (0.50) | CYP17A1PSMB8NAMPTHDAC3HDAC1 | |
| SCHEMBL14090975 | 0.81 | HDAC3 (0.53) | CYP17A1NAMPTHDAC3HDAC1HDAC2 | |
| SCHEMBL1922120 | 0.81 | CYP17A1 (0.52) | CYP17A1PSMB8NAMPTCA12CA1 | |
| SCHEMBL21339831 | 0.81 | MIF (0.52) | CYP17A1PSMB8NAMPTHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544463-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | FIVE ELEVEN PHARMA INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4663637-A2 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | Five Eleven Pharma Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12297381-B2 | Laminate, release agent composition, and method for manufacturing processed semiconductor substrate | NISSAN CHEMICAL CORPORATION (JP) | 2025-05-13 | — | — | US | disclosed |
| CN-119735766-A | Method for preparing cyclic polymer at high concentration and prepared cyclic polymer | 清华大学 | 2025-04-01 | — | — | CN | disclosed |
| CN-119735748-A | Preparation method of polymer with ring-chain hybridization structure and polymer with ring-chain hybridization structure | 清华大学 | 2025-04-01 | — | — | CN | disclosed |
| CN-115611781-B | New method for preparing alkyl sulfonamide from fatty amine sulfonyl chloride | 天津师范大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-114539243-B | Novel deuterium-substituted Positron Emission Tomography (PET) imaging agent and pharmacological application thereof | 五一一制药股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230295368-A1 | CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295368-A1 | CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT | KOEI CHEMICAL COMPANY, LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230265325-A1 | LAMINATE, RELEASE AGENT COMPOSITION, AND METHOD FOR MANUFACTURING PROCESSED SEMICONDUCTOR SUBSTRATE | NISSAN CHEMICAL CORPORATION (JP) | 2023-08-24 | — | — | US | disclosed |
| US-7229574-B2 | Method of making novel water-soluble and self-doped polyaniline graft copolymers | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2007-06-12 | — | — | US | disclosed |
| EP-1602481-B1 | Lithographic printing plate precursor | FUJIFILM CORP (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-20060051524-A1 | Hybrid polymer materials for liquid crystal alignment layers | ELSICON, INC. | 2006-03-09 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| US-6919404-B2 | Hybrid polymer materials for liquid crystal alignment layers | ELSICON, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20030232930-A1 | Hybrid polymer materials for liquid crystal alignment layers | ELSICON, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003102045-A1 | HYBRID POLYMER MATERIALS FOR LIQUID CRYSTAL ALIGNMENT LAYERS | ELSICON, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544463-B2 | Deuterium substituted positron emission tomography (PET) imaging agents and their pharmacological application | SLC18A2, SLC6A3, SLCO1B3 | CYP17A1 1250/4885PSMB8 2596/4885NAMPT 4475/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | CYP17A1 1039/4885PSMB8 2153/4885NAMPT 3451/4885 |
| US-20230295368-A1 | CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT | IDH3A, RCOR1, MUS81 | CYP17A1 1738/4885PSMB8 935/4885NAMPT 1467/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | CYP17A1 1877/4885PSMB8 963/4885NAMPT 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.